Denali Therapeutics Inc.
NasdaqGS:DNLI Stok Raporu
Denali Therapeutics Gelecekteki Büyüme
Future kriter kontrolleri 2/6 Denali Therapeutics kazanç ve gelirin sırasıyla yıllık 27% ve 64.1% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 27.8% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -36.9% olacağı tahmin edilmektedir.
Anahtar bilgiler Biotechs kazanç büyümesi 27.3% Gelir büyüme oranı 64.1% Gelecekteki özkaynak getirisi -36.9% Analist kapsamı Good
Son güncelleme 11 Nov 2024
Gelecekteki son büyüme güncellemeleri
Consensus revenue estimates decrease by 14% Aug 22
Consensus revenue estimates decrease by 45%, EPS upgraded Aug 08
Consensus revenue estimates fall by 29% May 14
Consensus revenue estimates decrease by 49% Mar 06
Price target decreased by 7.1% to US$48.53 Dec 18
Consensus EPS estimates upgraded to US$1.01 loss, revenue downgraded Nov 14
Tüm güncellemeleri göster
New major risk - Revenue size Nov 07
Co-Founder notifies of intention to sell stock Oct 20
Director notifies of intention to sell stock Oct 02
Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome) Sep 04
New minor risk - Insider selling Aug 25
Insider notifies of intention to sell stock Aug 23
Consensus revenue estimates decrease by 14% Aug 22
Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology Aug 20
Consensus revenue estimates decrease by 45%, EPS upgraded Aug 08
First half 2024 earnings released: US$1.27 loss per share (vs US$0.53 profit in 1H 2023) Aug 02
Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth Jul 26
Director notifies of intention to sell stock Jul 04
Now 21% undervalued Jun 17
Revenues Not Telling The Story For Denali Therapeutics Inc. (NASDAQ:DNLI) After Shares Rise 25% May 23
Consensus revenue estimates fall by 29% May 14
Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data May 13
New major risk - Revenue and earnings growth May 09
First quarter 2024 earnings released: US$0.68 loss per share (vs US$0.80 loss in 1Q 2023) May 08
Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating Eif2b Agonist Dnl343 in the Phase 2/3 Healey ALS Platform Trial May 01
Denali Therapeutics Inc., Annual General Meeting, May 31, 2024 Apr 20
An Intrinsic Calculation For Denali Therapeutics Inc. (NASDAQ:DNLI) Suggests It's 44% Undervalued Apr 17
Director notifies of intention to sell stock Apr 03
New minor risk - Shareholder dilution Mar 24
Denali Therapeutics Inc.'s (NASDAQ:DNLI) Price Is Right But Growth Is Lacking After Shares Rocket 25% Mar 21
Denali: Leveraging Transport Vehicle Technology For Neurological Gains Mar 07
Consensus revenue estimates decrease by 49% Mar 06
Full year 2023 earnings: EPS and revenues miss analyst expectations Feb 28 Denali Therapeutics Inc. announced that it expects to receive $499.73271 million in funding from Baker Bros. Advisors LP Feb 27
Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth Feb 21
Co-Founder notifies of intention to sell stock Feb 16
Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier-Crossing Enzyme Replacement Therapy Programs At Worldsymposium Feb 07
Denali Therapeutics Inc. Announces Presentations on Its Investigational Blood-Brain Barrier (Bbb)-Crossing Enzyme Replacement Therapies At the Upcoming 2024 Worldsymposium Feb 02
Insufficient new directors Feb 01
Improved Revenues Required Before Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Find Their Feet Jan 26
Co-Founder recently sold US$340k worth of stock Jan 11
Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases Jan 08
Co-Founder notifies of intention to sell stock Jan 08
Price target decreased by 7.1% to US$48.53 Dec 18
We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate Nov 20
Consensus EPS estimates upgraded to US$1.01 loss, revenue downgraded Nov 14
Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 09
Investor Optimism Abounds Denali Therapeutics Inc. (NASDAQ:DNLI) But Growth Is Lacking Oct 09
Denali Therapeutics Inc. Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023 Aug 31
Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth Aug 22
Consensus revenue estimates increase by 279% Aug 15
Co-Founder notifies of intention to sell stock Aug 13
New major risk - Revenue and earnings growth Aug 10
Second quarter 2023 earnings: EPS and revenues exceed analyst expectations Aug 09
Co-Founder notifies of intention to sell stock Jul 24
Co-Founder notifies of intention to sell stock Jul 20
Co-Founder notifies of intention to sell stock Jun 19
Co-Founder notifies of intention to sell stock May 18
Consensus revenue estimates increase by 21%, EPS downgraded May 15
First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind May 10
Denali Therapeutics Inc.'s (NASDAQ:DNLI) Intrinsic Value Is Potentially 69% Above Its Share Price May 02
Consensus revenue estimates increase by 29% Apr 25
Co-Founder notifies of intention to sell stock Apr 24
Co-Founder exercised options and sold US$198k worth of stock Apr 17
Analysts Are More Bearish On Denali Therapeutics Inc. (NASDAQ:DNLI) Than They Used To Be Mar 04
Full year 2022 earnings: Revenues and EPS in line with analyst expectations Mar 01
Consensus EPS estimates fall by 18% Mar 01
Co-Founder recently sold US$105k worth of stock Feb 17
Denali Therapeutics Announces Presentations on Enzyme Transport Vehicle Development Programs for MPS Diseases at the Upcoming WORLDSymposium™ Feb 16
Co-Founder notifies of intention to sell stock Feb 13
Here's Why We're Not Too Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Situation Feb 06
Co-Founder notifies of intention to sell stock Jan 22
Co-Founder recently sold US$144k worth of stock Jan 11
Co-Founder notifies of intention to sell stock Jan 09
Denali Therapeutics Announces DNL343 Interim Phase 1B Data in ALS and Entry into the Healey ALS Platform Trial Dec 06
Consensus forecasts updated Nov 16
Consensus revenue estimates fall by 14% Nov 10
These Analysts Think Denali Therapeutics Inc.'s (NASDAQ:DNLI) Sales Are Under Threat Nov 09
Co-Founder notifies of intention to sell stock Nov 05
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Nov 04
Consensus revenue estimates increase by 10% Nov 03
Denali Therapeutics Announces Phase 1/2 Study Single Dose Healthy Volunteer Data with Tak-594/Dnl593 (Ptv:Pgrn) and Progression to Enrolling Participants with Ftd-Grn Nov 02
Denali Therapeutics proposes $250M stock offering; shares down 6% post market Oct 18
Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth Oct 12
Biogen, Denali begin dosing in late-stage trial of Parkinson's candidate BIIB122 Oct 10
Biogen Inc. and Denali Therapeutics Announce Initiation of the Phase 3 Lighthouse Study in Parkinson's Disease Associated with Lrrk2 Pathogenic Mutations Oct 04
Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) Sep 01
Insider notifies of intention to sell stock Aug 29
Insider recently sold US$86k worth of stock Aug 24
Second quarter 2022 earnings: EPS and revenues exceed analyst expectations Aug 09
Co-Founder recently sold US$712k worth of stock Jul 29
Co-Founder notifies of intention to sell stock Jun 27
We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate Jun 08
Denali Therapeutics and Biogen Announce Initiation of Phase 2B Study of Lrrk2 Inhibitor in Parkinson's Disease Jun 01
Price target decreased to US$72.83 May 14
Consensus revenue estimates increase by 21% May 12
First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind May 06
Denali Therapeutics Inc. Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in ALS by Sanofi May 03
Denali Therapeutics Inc., Annual General Meeting, Jun 02, 2022 Apr 20
Co-Founder recently sold US$677k worth of stock Mar 29
Kazanç ve Gelir Büyüme Tahminleri NasdaqGS:DNLI - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions ) Tarih Gelir Kazançlar Serbest Nakit Akışı Faaliyetlerden Nakit Avg. Analist Sayısı 12/31/2026 240 -417 -302 -235 10 12/31/2025 66 -483 -451 -283 13 12/31/2024 12 -445 -408 -361 14 9/30/2024 N/A -427 -376 -363 N/A 6/30/2024 1 -420 -402 -391 N/A 3/31/2024 295 -137 -425 -413 N/A 12/31/2023 331 -145 -371 -358 N/A 9/30/2023 341 -124 -348 -332 N/A 6/30/2023 343 -128 -321 -302 N/A 3/31/2023 101 -371 -248 -231 N/A 12/31/2022 108 -326 -263 -245 N/A 9/30/2022 111 -303 -254 -238 N/A 6/30/2022 112 -284 -234 -222 N/A 3/31/2022 83 -286 -243 -233 N/A 12/31/2021 49 -291 -220 -211 N/A 9/30/2021 353 30 361 368 N/A 6/30/2021 357 56 404 410 N/A 3/31/2021 340 58 415 420 N/A 12/31/2020 336 71 413 416 N/A 9/30/2020 24 -228 -150 -145 N/A 6/30/2020 28 -216 -183 -176 N/A 3/31/2020 26 -215 -193 -176 N/A 12/31/2019 27 -198 -169 -152 N/A 9/30/2019 148 -66 -27 -11 N/A 6/30/2019 135 -55 -30 -15 N/A 3/31/2019 133 -52 -19 -14 N/A 12/31/2018 129 -36 47 50 N/A 9/30/2018 3 -137 -64 -61 N/A 6/30/2018 2 -123 N/A -49 N/A 3/31/2018 1 -91 N/A -24 N/A 12/31/2017 N/A -88 N/A -77 N/A 9/30/2017 N/A -85 N/A -77 N/A 6/30/2017 N/A -93 N/A -76 N/A 3/31/2017 N/A -90 N/A -75 N/A 12/31/2016 N/A -87 N/A -72 N/A
Daha fazla göster
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: DNLI önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.
Kazançlar ve Piyasa: DNLI önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.
Yüksek Büyüme Kazançları: DNLI önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.
Gelir ve Pazar: DNLI şirketinin gelirinin (yıllık 64.1% ) US pazarından (yıllık 8.9% ) daha hızlı büyümesi öngörülüyor.
Yüksek Büyüme Geliri: DNLI şirketinin gelirinin (yıllık 64.1% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: DNLI 3 yıl içinde kârsız olması bekleniyor.
Büyüyen şirketleri keşfedin Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
